Scorpion Partners Two Assets With Pierre Fabre To Prioritize Investment In A Third
The oncology start-up signed a co-development and commercialization agreement with the French pharmaceutical company for two next-generation EGFR inhibitors.
You may also be interested in...
Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.
Agreement with Alexion is JCR’s first international deal for its blood-brain barrier drug delivery technology. Sartoris buys PolyPlus from private equity investors.
The UK major will work with the US biotech to develop up to three precision medicines targeting cancer proteins previously thought undruggable via conventional methods.